Download presentation
Presentation is loading. Please wait.
Published byAmbrose Lawson Modified over 5 years ago
1
Identifying TRK Fusions in Head and Neck Cancer
3
Introduction
4
Overview of NTRK
5
NTRK Fusions
6
Frequency of NTRK Fusions
7
NTRK Fusions in Salivary Gland and Thyroid Cancers
8
Identifying Appropriate Patients for NTRK Testing
9
Identifying Appropriate Patients for NTRK Testing, cont
10
Challenges in Identifying Secretory Histology in Salivary Gland Cancer
11
Optimal Timing for NTRK Testing
12
NTRK Fusions vs Point Mutations
13
Testing for TRK Fusions
14
NTRK Inhibitors
15
Overview of Larotrectinib Clinical Trials
16
Larotrectinib in Subset of Patients With Salivary Gland and Thyroid Cancers
17
Larotrectinib in Subset of Patients With Salivary Gland and Thyroid Cancers (cont)
18
Larotrectinib Clinical Trials: 2019 Update
19
Select Larotrectinib TRAEs in Clinical Trials
20
Overview of Entrectinib Clinical Trials
21
Resistance to TRK Inhibitors
22
LOXO-195 in Larotrectinib-Resistant Patients
23
Repotrectinib in Larotrectinib-Resistant Patients
24
Unanswered Questions
25
Summary and Conclusions
26
Abbreviations
27
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.